Lyell Immunopharma, Inc.
About Lyell Immunopharma, Inc.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $36.0K
- Net income
- -$274.4M
- Total assets
- $340.1M
- Market cap
- $279.3M
- Operating margin
- -748344.4%
- Net margin
- -762355.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $36.0K
- Operating expenses
- $269.4M
- Operating income
- -$269.4M
- Income tax
- $0
- Net income
- -$274.4M
- EPS (basic)
- $-16.06
- EPS (diluted)
- $-16.06
Balance sheet
- Total assets
- $340.1M
- Current assets
- $260.9M
- Total liabilities
- $91.8M
- Current liabilities
- $49.4M
- Shareholders’ equity
- $248.2M
Cash flow
- Operating cash flow
- -$150.0M
- Investing cash flow
- $54.1M
- Financing cash flow
- $50.4M
- Net cash flow
- -$45.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $279.3M
- EPS (diluted)
- $-16.06
- Shares outstanding
- 22.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 17, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $274.4M in FY2025.
- Revenue declined 100% from FY2021 to FY2025.
- Trading 68% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lyell Immunopharma, Inc..
Write a review
News about Lyell Immunopharma, Inc.
News & sentiment via Polygon.io
